In the context of cancer, the blockade of the PD-1/PD-L1 axis, either through anti-PD-1 administration or SHP-1 deletion in nociceptors, has been shown to aggravate cancer pain in mouse models of melanoma and bone cancer (138, 139). This evidence concerns the gene PDCD1 and melanoma.